Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Christiana Stamoulis net worth and biography

Christiana Stamoulis Biography and Net Worth

Director of Hologic

Ms. Stamoulis has been a member of our board since November 2011. In February 2019, Ms. Stamoulis assumed the role of Executive Vice President and Chief Financial Officer of Incyte Corporation. From January 2015 to the end of January 2019, Ms. Stamoulis served as Chief Financial Officer of Unum Therapeutics, adding the role of President in February 2018. Prior to Unum, she was an independent advisor to biopharmaceutical companies from January 2014 to December 2014. Prior to that, Ms. Stamoulis served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals Incorporated from 2009 to 2013. Ms. Stamoulis joined Vertex in 2009 with approximately 15 years of experience in the investment banking and management consulting industries where she advised global pharmaceutical and biotechnology companies on strategic and corporate finance decisions. Prior to joining Vertex, she was a Managing Director in the Investment Banking division of Citigroup from 2006 to 2009 where she led the building of the firm’s U.S. Life Sciences investment banking practice. Prior to her role at Citigroup, she was at Goldman, Sachs & Co. where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis holds a Bachelor of Science degree in Economics and a Bachelor of Science degree in Architecture from the Massachusetts Institute of Technology (MIT). Additionally, she holds a Master of Business Administration from the MIT Sloan School of Management where she focused on Applied Economics and Finance.

What is Christiana Stamoulis' net worth?: The estimated net worth of Christiana Stamoulis is at least $3.26 million as of July 17th, 2024. Ms. Stamoulis owns 45,472 shares of Hologic stock worth more than $3,258,069 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Stamoulis may own. Learn More about Christiana Stamoulis' net worth.
How do I contact Christiana Stamoulis?: The corporate mailing address for Ms. Stamoulis and other Hologic executives is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. Hologic can also be reached via phone at (508) 263-2900 and via email at [email protected]. Learn More on Christiana Stamoulis' contact information.
Has Christiana Stamoulis been buying or selling shares of Hologic?: Christiana Stamoulis has not been actively trading shares of Hologic during the past quarter. Most recently, Christiana Stamoulis sold 9,039 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a transaction totalling $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company's stock, valued at $3,615,024. Learn More on Christiana Stamoulis' trading history.
Who are Hologic's active insiders?: Hologic's insider roster includes Benjamin Cohn (Insider), Sally Crawford (Director), Sean Daugherty (Insider), Charles Dockendorff (Director), Scott Garrett (Director), John Griffin (General Counsel), Stephen Macmillan (Chairman, CEO & President), Essex Mitchell (Insider), Karleen Oberton (CFO), Brandon Schnittker (Division President, Surgical Solutions), Christiana Stamoulis (Director), Kevin Thornal (Insider), Peter Valenti, III (Insider), and Jan Verstreken (Insider). Learn More on Hologic's active insiders.
Are insiders buying or selling shares of Hologic?: During the last twelve months, insiders at the medical equipment provider sold shares 8 times. They sold a total of 75,982 shares worth more than $5,840,923.48. The most recent insider tranaction occured on December, 4th when COO Essex D Mitchell sold 24,856 shares worth more than $1,897,507.04. Insiders at Hologic own 1.8% of the company. Learn More about insider trades at Hologic.
Information on this page was last updated on 12/4/2024.

Christiana Stamoulis Insider Trading History at Hologic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2024	Sell	9,039	$79.50	$718,600.50	45,472
11/22/2019	Sell	12,306	$49.75	$612,223.50	49,481
11/28/2018	Sell	13,257	$44.50	$589,936.50	48,296
10/2/2018	Sell	30,967	$40.70	$1,260,356.90	66,006

Christiana Stamoulis Buying and Selling Activity at Hologic

Hologic Company Overview

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $71.65

$70.36

$71.95

50 Day Range

MA: $78.65

$70.76

$83.72

2 Week Range

Now: $71.65

$70.36

$84.67

Volume

8,560,791 shs

Average Volume

1,672,050 shs

Market Capitalization

$16.26 billion

P/E Ratio

21.52

Dividend Yield

N/A

Beta

0.96

First JFK… next Elon?

From Porter & Company | Ad